Subscribe
shutterstock_1919150828_margarett24
Margarett24 / Shutterstock.com
19 August 2021AmericasRory O'Neill

Nexus and Nevakar face off over hypotension drug

Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Medicure and Nexus agree Aggrastat generic licence
20 November 2020   US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.
Americas
FDA approves milestone biosimilar insulin drug
29 July 2021   The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.
Big Pharma
Pharma company raises pressure with hypotension drug lawsuit
13 October 2022   Nexus raises second complaint against same parties in a month | Ready-to-use drug that can raise the blood pressure of hypotension patients at issue.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Medicure and Nexus agree Aggrastat generic licence
20 November 2020   US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.
Americas
FDA approves milestone biosimilar insulin drug
29 July 2021   The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.
Big Pharma
Pharma company raises pressure with hypotension drug lawsuit
13 October 2022   Nexus raises second complaint against same parties in a month | Ready-to-use drug that can raise the blood pressure of hypotension patients at issue.

More on this story

Americas
Medicure and Nexus agree Aggrastat generic licence
20 November 2020   US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.
Americas
FDA approves milestone biosimilar insulin drug
29 July 2021   The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.
Big Pharma
Pharma company raises pressure with hypotension drug lawsuit
13 October 2022   Nexus raises second complaint against same parties in a month | Ready-to-use drug that can raise the blood pressure of hypotension patients at issue.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York